MELD 3.0: Updated MELD Score For Liver Transplantation

Why MELD 3.0 Was Created

The original MELD score (based on bilirubin, creatinine, and INR) has been the backbone of liver allocation in the United States since 2002. It predicts short-term mortality and helps ensure that livers go to the sickest appropriate patients first, rather than favoring “time on the list.”^[4]

Over time, however, clinicians and policy makers identified two key problems:

• MELD did not fully capture the risk associated with low albumin and hyponatremia.
• Women consistently had lower transplant rates and higher waitlist mortality compared with men, in part because creatinine underestimates kidney dysfunction in people with lower muscle mass.^[2][5]

In response, the OPTN Liver Committee sponsored the development of MELD 3.0, an updated model that:

• Adds albumin and a term for female sex.
• Updates the coefficients for bilirubin, creatinine, INR, and sodium.
• Introduces interaction terms between bilirubin/sodium and albumin/creatinine.
• Caps creatinine at 3.0 mg/dL to avoid over-penalizing patients with very high creatinine.^[1][3]

MELD 3.0 went into effect for allocation on July 13, 2023 and is now the standard MELD score used in liver transplant allocation in the United States for candidates 12 years and older.^[3][6]

Variables & Bounds In MELD 3.0

MELD 3.0 uses the following variables:

• Serum bilirubin (mg/dL) – measure of bile excretion.
• Serum creatinine (mg/dL) – marker of kidney function.
• INR – reflects blood clotting and liver synthetic function.
• Serum sodium (mmol/L) – measures hyponatremia and fluid balance.
• Serum albumin (g/dL) – reflects nutritional status and liver synthetic function.
• Sex (for the purposes of MELD calculation) – 1.33 points are added if the candidate is classified as female for MELD.^[1][3]

To keep the model stable and clinically realistic, MELD 3.0 applies specific bounds:

• Bilirubin, creatinine, INR: values less than 1.0 are set to 1.0.
• Creatinine: capped at a maximum of 3.0 mg/dL; if the patient has had qualifying dialysis, creatinine is treated as 3.0 mg/dL.^[1][3]
• Sodium: capped between 125 and 137 mmol/L in MELD 3.0 calculators.^[7][8]
• Albumin: capped between 1.5 and 3.5 g/dL.^[7]

These bounds are implemented in major MELD 3.0 calculators used by transplant clinicians and academic centers, including university-hosted calculators and OPTN-linked tools.^[7][8]

How MELD 3.0 Works (Concept, Not Math)

Mathematically, MELD 3.0 is a logarithmic regression model built from a large national cohort of liver transplant candidates. The final formula includes:

• Log-transformed bilirubin, creatinine, and INR.
• Linear terms for sodium and albumin.
• Interaction terms between sodium and bilirubin, and between albumin and creatinine.
• A 1.33-point term for female sex, plus a constant of 6.^[1][3][9]

In the original Gastroenterology paper and subsequent analyses, MELD 3.0:

• Showed slightly better discrimination for 90-day waitlist mortality than MELD-Na.
• Correctly reclassified about 9% of patients who died into a higher priority tier, particularly women.
• Reduced simulated waitlist deaths in allocation models compared with MELD-Na.^[1][9]

You do not need to memorize the formula. In real life, your transplant team uses certified calculators (such as the OPTN MELD calculator and center-specific tools) that automatically apply the correct math and policy rules.^[6][10]

Equity & Sex Disparities With MELD 3.0

Before MELD 3.0, multiple studies showed that women had lower transplant rates and higher waitlist mortality than men, even at similar MELD-Na scores. Lower average muscle mass in women led to lower creatinine levels, which made liver and kidney dysfunction look “better” than it really was in the older MELD models.^[2][5]

MELD 3.0 addresses this by:

• Adding a 1.33-point term for female sex.
• Including albumin and updated creatinine coefficients.
• Improving accuracy particularly in patients with lower muscle mass.^[1][3]

Early post-implementation data and AASLD reports show that MELD 3.0 has narrowed sex-based disparities: waitlist mortality for women has decreased, and transplant rates for women now more closely match those for men, without harming overall outcomes.^[2][11][12]

Labs, Monitoring & Policy Under MELD 3.0

When MELD 3.0 was implemented, OPTN also updated how often candidates need lab updates and what data are required in the allocation system:

• Albumin is now required for all MELD candidates (age ≥12) because it is part of the score.
• Transplant programs must record “Sex for purposes of adult MELD calculation” for adult candidates so that the 1.33 female-sex points are applied correctly.^[3][6]
• Lab update schedules (how often MELD must be re-checked) depend on the current MELD value, with higher scores requiring more frequent labs.^[6][10]

From the patient perspective, this means:

• You will have regular blood tests while on the waitlist—often every 7–30 days depending on your score.
• Your MELD 3.0 can go up or down as your labs change; your team will track trends over time.^[13][14]
• Your overall transplant priority also depends on factors like exceptions (for HCC and other conditions) and your local median MELD at transplant (MMaT).

MELD 3.0 Calculator (Educational Use Only)

This built-in calculator uses the published MELD 3.0 formula with standard bounds for bilirubin, creatinine, INR, sodium, and albumin. It is for education only and may not exactly match the official OPTN calculator or your center’s system. Never use this tool to make emergency decisions—always rely on your transplant team and official calculators.^[1][3][7]

Patient Story: Understanding MELD 3.0

Lisa is a 55-year-old woman with cirrhosis from nonalcoholic steatohepatitis (NASH). When she was first evaluated for transplant, her bilirubin was only mildly elevated, but her albumin was low and she had progressive ascites and hyponatremia. Under the older MELD-Na model, her score hovered around 14–15.

After MELD 3.0 was implemented, her albumin and sex were incorporated into the score. Her MELD 3.0 rose into the high teens and then low 20s as her disease advanced. Her transplant team explained that the new model was “seeing” her risk more clearly than before.

Over several months, Lisa’s MELD 3.0 continued to rise. She and her family kept a simple notebook with dates, lab values, and scores, and they used an educational calculator—similar to the one on this page—to better understand how changes in sodium, albumin, and creatinine affected her score. The real decisions, however, were always guided by her hepatologist and transplant coordinator.

When her MELD 3.0 reached the high 20s, she received an organ offer and proceeded to transplant. After recovery, she describes MELD 3.0 as “the number that finally told the story of how sick I really was”—not a judgment, but a tool to get her the help she needed.

References

1. Kim WR et al. MELD 3.0: The model for end-stage liver disease updated for the modern era. Gastroenterology. 2021. Primary development paper describing the MELD 3.0 formula, variables, performance, and reclassification of high-risk candidates.
2. AASLD. Updated model reduces liver transplant disparities for women (MELD 3.0). Describes how MELD 3.0 reduces sex-based disparities in liver transplant access and waitlist mortality.
3. OPTN. Improving Liver Allocation: MELD 3.0 FAQ. 2023. Policy FAQ explaining MELD 3.0 implementation, variable changes, creatinine cap, sex term, and albumin requirements.
4. Moylan CA et al. Disparities in liver transplantation before and after MELD. JAMA. 2008. Classic paper on MELD-based allocation and early recognition of disparities.
5. Ge J et al. “Beyond MELD” – Emerging strategies and technologies in liver allocation. J Hepatol. 2022. Reviews limitations of MELD/MELD-Na and discusses sex- and size-related disparities in liver transplantation.
6. UNOS. Improvements to MELD and PELD now in effect. July 13, 2023. Announcement of MELD 3.0 implementation and related data-collection changes (albumin, sex for MELD).
7. Hepatitis C Online (UW). MELD 3.0 calculator and documentation. Describes variable bounds for sodium (125–137 mmol/L), albumin (1.5–3.5 g/dL), and creatinine cap at 3.0 mg/dL.
8. Fix O. MELD 3.0 web calculator. Clinical calculator showing MELD, MELD-Na, and MELD 3.0 with standard bounds and inputs.
9. Kim WR et al. MELD 3.0 supporting analyses. Gastroenterology. 2021. Full-text analysis of model discrimination, calibration, and simulated allocation impact for MELD 3.0.
10. OPTN. MELD calculator (official allocation tool). Official MELD/MELD 3.0 calculator used in U.S. liver allocation and associated user guide.
11. GI & Hepatology News. MELD 3.0 reduces sex-based liver transplant disparities. 2024. News coverage of data showing improved equity for women after MELD 3.0 implementation.
12. OPTN. MELD 3.0 and PELD-CR 12-month monitoring report. 2025. Early post-implementation monitoring of MELD 3.0, including mortality and transplant access outcomes.
13. Mayo Clinic. MELD score for liver disease. Patient-oriented explanation of MELD scores, their 6–40 range, and how they are used in listing and allocation.
14. NIDDK. The liver transplant process: Preparing for a transplant. Overview of evaluation, waitlist placement, and monitoring for liver transplant candidates.